Suppr超能文献

ABO血型不匹配与异基因造血细胞移植后非复发死亡率增加有关。

ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

作者信息

Logan Aaron C, Wang Zhiyu, Alimoghaddam Kamran, Wong Ruby M, Lai Tze, Negrin Robert S, Grumet Carl, Logan Brent R, Zhang Mei-Jie, Spellman Stephen R, Lee Stephanie J, Miklos David B

机构信息

Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, California.

Health Research and Policy, Stanford University School of Medicine, Stanford, California.

出版信息

Biol Blood Marrow Transplant. 2015 Apr;21(4):746-54. doi: 10.1016/j.bbmt.2014.12.036. Epub 2015 Jan 5.

Abstract

We evaluated ABO associated outcomes in 1737 patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) at Stanford University between January 1986 and July 2011. Grafts were 61% ABO matched, 18% major mismatched (MM), 17% minor MM, and 4% bidirectional MM. Median follow-up was 6 years. In multivariate analysis, overall survival (OS) was inferior in minor MM hematopoietic cell transplantations (median 2.1 versus 6.3 years; hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.19 to 2.05; P = .001) in comparison with ABO-matched grafts. ABO minor MM was associated with an increase in early nonrelapse mortality (NRM) (18% versus 13%; HR, 1.48; 95% CI, 1.06 to 2.06; P = .02). In an independent Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 435 lymphoma patients receiving mobilized peripheral blood grafts, impairment of OS (HR, 1.55; 95% CI, 1.07 to 2.25; P = .021) and increased NRM (HR, 1.72; 95% CI, 1.11 to 2.68; P = .03) were observed in recipients of ABO minor-MM grafts. A second independent analysis of a CIBMTR data set including 5179 patients with acute myeloid leukemia and myelodysplastic syndrome identified a nonsignificant trend toward decreased OS in recipients of ABO minor-MM grafts and also found ABO major MM to be significantly associated with decreased OS (HR, 1.19; 95% CI, 1.08 to 1.31; P < .001) and increased NRM (HR, 1.23; 95% CI, 1.08 to 1.4; P = .002). ABO minor and major MM are risk factors for worse transplantation outcomes, although the associated hazards may not be uniform across different transplantation populations. Further study is warranted to determine which patient populations are at greatest risk, and whether this risk can be modified by anti-B cell therapy or other peri-transplantation treatments.

摘要

我们评估了1986年1月至2011年7月期间在斯坦福大学接受异基因造血细胞移植(allo-HCT)的1737例患者中与ABO血型相关的结局。移植物的ABO血型匹配率为61%,主要错配(MM)率为18%,次要MM率为17%,双向MM率为4%。中位随访时间为6年。在多变量分析中,与ABO血型匹配的移植物相比,次要MM造血细胞移植的总生存期(OS)较差(中位生存期分别为2.1年和6.3年;风险比[HR]为1.56;95%置信区间[CI]为1.19至2.05;P = 0.001)。ABO次要MM与早期非复发死亡率(NRM)增加相关(18%对13%;HR为1.48;95%CI为1.06至2.06;P = 0.02)。在国际血液和骨髓移植研究中心(CIBMTR)对435例接受动员外周血移植物的淋巴瘤患者进行的独立分析中,观察到ABO次要MM移植物受者的OS受损(HR为1.55;95%CI为1.07至2.25;P = 0.021)和NRM增加(HR为1.72;95%CI为1.11至2.68;P = 0.03)。对CIBMTR数据集进行的第二项独立分析,该数据集包括5179例急性髓系白血病和骨髓增生异常综合征患者,发现ABO次要MM移植物受者的OS有下降趋势但无统计学意义,同时还发现ABO主要MM与OS降低(HR为1.19;95%CI为1.08至1.31;P < 0.001)和NRM增加(HR为1.23;95%CI为1.08至1.4;P = 0.002)显著相关。ABO次要和主要MM是移植结局较差的危险因素,尽管不同移植人群的相关风险可能并不一致。有必要进一步研究以确定哪些患者群体风险最大,以及这种风险是否可以通过抗B细胞疗法或其他移植围手术期治疗来改善。

相似文献

1
ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2015 Apr;21(4):746-54. doi: 10.1016/j.bbmt.2014.12.036. Epub 2015 Jan 5.
2
Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source.
Biol Blood Marrow Transplant. 2017 May;23(5):795-804. doi: 10.1016/j.bbmt.2017.02.009. Epub 2017 Feb 14.
5
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
Am J Hematol. 2023 Apr;98(4):608-619. doi: 10.1002/ajh.26834. Epub 2023 Jan 16.
7
Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
Transfus Clin Biol. 2020 Aug;27(3):115-121. doi: 10.1016/j.tracli.2020.06.008. Epub 2020 Jul 10.
10
Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Biol Blood Marrow Transplant. 2015 May;21(5):873-80. doi: 10.1016/j.bbmt.2015.01.019. Epub 2015 Jan 23.

引用本文的文献

3
Donor Selection for Allogeneic Hematopoietic Cell Transplantation.
Dtsch Arztebl Int. 2023 Apr 14;120(15):261-268. doi: 10.3238/arztebl.m2023.0031.
4
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
Am J Hematol. 2023 Apr;98(4):608-619. doi: 10.1002/ajh.26834. Epub 2023 Jan 16.
5
[ABO incompatibility and complications in hematopoietic stem cell transplantation].
Rev Med Inst Mex Seguro Soc. 2023 Jan 1;61(Suppl 1):S12-S18.
6
Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.
Blood Adv. 2022 Apr 26;6(8):2707-2721. doi: 10.1182/bloodadvances.2021006279.
9
ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes.
Transplant Direct. 2021 Jul 9;7(8):e724. doi: 10.1097/TXD.0000000000001179. eCollection 2021 Aug.
10

本文引用的文献

3
Sequential design of phase II-III cancer trials.
Stat Med. 2012 Aug 15;31(18):1944-60. doi: 10.1002/sim.5346. Epub 2012 Mar 16.
4
Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.
Bone Marrow Transplant. 2011 Sep;46(9):1167-85. doi: 10.1038/bmt.2011.135.
5
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
Bone Marrow Transplant. 2012 Feb;47(2):203-11. doi: 10.1038/bmt.2011.69. Epub 2011 Mar 28.
6
Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival.
Bone Marrow Transplant. 2011 Jul;46(7):981-6. doi: 10.1038/bmt.2010.218. Epub 2010 Oct 4.
7
Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.
Biol Blood Marrow Transplant. 2010 Sep;16(9):1315-23. doi: 10.1016/j.bbmt.2010.03.021. Epub 2010 Mar 29.
8
Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
Transplant Proc. 2009 Nov;41(9):3851-8. doi: 10.1016/j.transproceed.2009.06.189.
9
Selection of adult unrelated hematopoietic stem cell donors: beyond HLA.
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S8-S11. doi: 10.1016/j.bbmt.2009.10.031. Epub 2009 Nov 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验